Glenmark Pharmaceuticals rises on the BSE
Glenmark Pharmaceuticals is currently trading at Rs. 1659.35, up by 5.60 points or 0.34% from its previous closing of Rs. 1653.75 on the BSE.
The scrip opened at Rs. 1653.15 and has touched a high and low of Rs. 1661.95 and Rs. 1637.60 respectively. So far 3425 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1830.05 on 15-Oct-2024 and a 52 week low of Rs. 1199.95 on 26-Jun-2024.
Last one week high and low of the scrip stood at Rs. 1690.95 and Rs. 1605.50 respectively. The current market cap of the company is Rs. 46900.36 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 37.80% and 15.56% respectively.
United States Food & Drug Administration (USFDA) has concluded GMP inspection at Glenmark Pharmaceuticals’ manufacturing facility situated in Monroe, North Carolina, USA. The inspection was conducted from June 09 to June 17, 2025.
At the end of the inspection, the Company was issued a Form 483 with five observations. All the observations are procedural in nature. There was no observation related to data integrity reported. The Company will work in close collaboration with the agency to address the observations and will respond to the USFDA within the stipulated timeline.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
